The limiting factor in the clinical use of misonidazole (MISO) as a radiosensitizer is its neurotoxicity and, because of this, a maximum oral dose of 12gm 2 is usually advocated (Dische et al., 1977; Urtasun et al., 1978; Wasserman et al., 1979; Bleehen, 1980) . In a fractionated course of radiotherapy, it is likely that the dose of MISO given with each treatment is inadequate to produce measurable radiosensitization. This has led investigators to study the role of pretreatment with enzyme inducers (phenytoin, phenobarbitone, antipyrene) , such that the resulting reduction in half life and area under the curve (AUC) may allow an increase in dose, without any increase in toxicity (Bleehen, 1980; Workman et al., 1980; Wasserman et al., 1980; Moore et al., 1981) . Such a theoretical basis does not prove to be as satisfactory as expected in the clinical setting, in that, despite the above changes in MISO plasma pharmacokinetics, the incidence of neurotoxicity remains unchanged, and the dose of MISO cannot safely be increased above 12 gm 2 (Jones et al., 1983) .
It has been noted that patients with glioma, treated with radiotherapy and MISO, may not show the expected incidence of central and/or peripheral neurotoxicity (Bleehen, 1980) . That these patients are concurrently taking enzyme-inducing anticonvulsants may be a plausible explanation for this observation, but in the light of our other recent studies mentioned above (Jones et al., 1983) Frequently, patients with gliomas are given glucocorticoids for the control of cerebral oedema either due to the tumour itself or due to surgery or radiotherapy. Dexamethasone is the drug most usually used. Initial studies in laboratory animals showed that dexamethasone does not seem to affect the plasma pharmacokinetics of MISO (Workman, 1980a) . Further, a review of MISO plasma pharmacokinetics in a heterogeneous group of 83 patients indicated that, in man, both enzyme inducers and dexamethasone influence the body's handling of MISO. For this reason, within patient plasma pharmacokinetic studies were executed to elucidate further the 'protective' property of dexamethazone in patients taking MISO.
Materials and methods
In the heterogeneous group of 83 consecutive patients receiving MISO in various doses whilst undergoing radiation therapy for a spectrum of tumours other than glioma, 43 were not taking steroids or enzyme inducers (phenytoin and/or phenobarbitone); 10 were taking steroids, but not any enzyme inducers; 25 were taking enzyme inducers, but no steroids; 5 were taking both steroids and enzyme inducers. The present study investigated 5 patients (4 males, 1 female) of mean age 50 years (range 35-68), who were previously untreated and who were not taking any other medication. In view of the recognised complications of steroid therapy, we felt that it was unethical to give steroids to patients who would not otherwise (Workman et al., 1978) and calculation of pharmacokinetic parameters was carried out as described previously (Workman, 1980b) . One patient agreed to undergo 51Cr-EDTA clearance studies as an index of glomerular filtration rate on the two occasions of MISO adminstration.
The patients' informed consent for the investigation was obtained and the study was approved by the hospital ethical committee.
Results
There were no acute adverse reactions due to dexamethasone or MISO. All patients completed their radiation regimen without deviation from the protocol. Pretreatment renal and hepatic function (Bleehen, 1980) we reviewed the results of MISO pharmacokinetic studies in a large group of patients who did not have glioma. Those patients who were not taking enzyme inducers but who were taking steroids had a significantly lower MISO plasma elimination half life than those not taking steroids. Such a difference was not seen in patients who were taking enzyme inducers, and their plasma elimination half lives were similar to published values for patients taking enzyme inducers..
As a result of these findings, laboratory studies were conducted to investigate the effect of dexamethasone on the pharmacokinetics of MISO in laboratory animals. We have reported (Workman, 1980a) difference in MISO elimination half life, AUC, percent drug recovery in urine, or peak plasma concentrations in the patients treated with dexamethasone. Their findings led them to postulate that dexamethasone "protects" by stabilising cell membranes, and altering cell surface properties, especially in demyelinated neurones.
In our present study, the aim was to investigate the pharmacokinetics of MISO before and after dexamethasone. By using each patient as his/her own control, it is easier to identify small changes in pharmacokinetics. Previous studies (Dische et al. 1977; Workman et al., 1980b) have shown that the pharmacokinetics of MISO do not change with repeated administrations, and therefore any alteration can be attributed to the effects of the dexamethasone. The total dose of MISO used was unlikely to produce any neurotoxicity -and such a dose was chosen as we were not concerned with neurotoxicity as the endpoint of this study. The dose of dexamethasone used by us was slightly higher than that of Urtasun et al. (1982) but was also given for 3 weeks, and given during the radiotherapy, not before.
The present results show a statistically significant effect of dexamethasone on MISO kinetics. The plasma MISO elimination half life value is almost exactly the same as that reported in the Cambridge glioma trial for patients who did not experience neurotoxicity (Bleehen et al., 1981) . The reduction in elimination half life and AUC, and the rise in urinary excretion of MISO, together with observation that there is no change in desmethylmisonidiazole AUC and urinary excretion, suggest that dexamethasone does not cause an induction of the microsomal enzymes responsibile for 0-demethylation. However, it is possible that a selective increase in urinary clearance of MISO (but not desmethylmisonidazole) occurs at the renal tubular level. Glucocorticoids can increase glomerular filtration rate, as well as producing a stimulatory influence on tubular secretion (Haynes & Lamer, 1975) . The results of the glomerular filtration studies performed in one patient showed no change after dexamethasone treatment. This leads us to assume that the increased clearance of MISO is probably the result of a steroid-induced increase in tubular secretion. Unfortunately there is no information on the tubular secretion of MISO.
It is, of course, possible that the "protective" effect of dexamethasone as regards neurotoxicity is a direct effect on the peripheral nerves, as postulated by Urtasun (1982J, and that the changes in pharmacokinetics do not play a role in this context. However, the significant changes in the pharmacokinetics described in the present study indicate that the sensitizer/steroid interaction must be carefully considered in future sensitizer studies -especially in the assessment and analysis of neurotoxicity. More detailed studies are needed on the renal handling of these nitroimidazoles, especially the effect of glucocorticoids in causing increased excretion. Oncol. Biol. Phys., 5, 775. WASSERMAN, T.H., PHILLIPS, T.L., VAN RAALTI, G. & 6 others (1980) . The neurotoxicity of misonidazole: potential modifying role of phenytoin sodium and dexamethazone (letter). Br. J. Radiol, 53, 172. 
